Why in news
- Union Health Ministry issued an advisory to States and UTs enforcing strict regulatory compliance for clinical stem cell therapy.
Key terms
Autism Spectrum Disorder
A developmental disability caused by differences in the brain affecting social interaction and communication.
Clinical Trial
A research study performed in human beings to evaluate the safety and efficacy of a medical intervention.
What is the Regulatory Framework?
- Governed primarily through the Clinical Establishments (Registration and Regulation) Act, 2010 and National Guidelines for Stem Cell Research, 2017.
- Formulated jointly by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT).
- Permits stem cell therapy as standard care in routine clinical practice only for specific disease indications approved by the Ministry of Health and Family Welfare.
Key Directives and Legal Mandate
- Advisory strictly restricts the therapeutic use of any type of stem cell for Autism Spectrum Disorder (ASD) solely to approved clinical trials.
- Implements the Supreme Court judgment in Yash Charitable Trust v. Union of India (2026 INSC 96).
- Mandates both government and private clinical establishments to refrain from promoting or administering unapproved stem cell procedures outside sanctioned research frameworks.
Why it matters
- Prevents unproven commercial stem cell treatments and protects patient rights against experimental procedures.
- Establishes strict legal liability for medical establishments engaging in non-compliant therapy.
Prelims facts
- Stem cell therapy for Autism Spectrum Disorder is permitted only in approved clinical trials, not standard care.
Mains discussion
- Ethical and regulatory challenges in overseeing experimental medical therapies in private healthcare institutions.
Source: PIB
Same topic · past papers
UPSC has asked this before
These previous-year questions sit on the same topic. Open one to practise the earlier ask.